A protein called LTBP3 fuels a chain reaction that leads some early developing tumors to grow new blood vessels and blocking this could give oncologist a chance to target tumors before they metastasize, shows study from The Scripps Research Institute (TSRI). The study, published in Oncogene shows that new blood vessels act like highways to spread cancer cells throughout the body, seeding metastatic tumors very early on.
"Lower LTBP3 levels appear to be associated with better prognosis in patients with certain types of cancer," says Elena Deryugina, PhD, an assistant professor at TSRI and first author of the new study. Deryugina led the collaborative study with senior authors James P. Quigley, PhD, a TSRI professor, and Daniel Rifkin, PhD, a professor at NYU School of Medicine.
Biomarker That can Identify the Metastasis Risk for Triple Negative Breast Cancers
New molecular biomarkers that could identify the aggressive subset of TNBCs and more offer patients promising options for treatment.
Advertisement
‘Knocking down LTBP3 which facilitates angiogenesis prevents the metastasis of primary tumor cells.’
Tweet it Now
Their research addresses a long-standing challenge in medicine. Over the years, a potent growth factor molecule called TGFβ has caught the eye of many cancer researchers. TGFβ has multiple roles in healthy people and in disease, and it can be both a promoter and suppresser of tumor cell growth. Although TGFβ has been a tempting cancer therapy target for a long time, scientists still do not know know how to dampen its harmful effects without interfering with its normal roles in the body.
As long-time collaborators, Deryugina and Quigley have led research that shows that the initial steps of tumor metastasis can occur when a primary tumor is barely detectable. This work sparked their interest in the role of LTBP3, short for Latent TGFβ Binding Protein 3. They knew that LTBP3 partners with TGFβ to regulate its secretion, activation and maturation, but wondered what else LTBP3 might control.
![Ovarian Cancer Metastasis can be Treated with a New Therapeutic Target]( "Ovarian Cancer Metastasis can be Treated with a New Therapeutic Target")
Ovarian metastasis can be treated with the inhibitors of a key cellular receptor called CXCR4, which could be a new therapeutic target.
Could LTBP3 set TGFβ on its harmful path of action in early-stage tumors, and might LTBP3 have its own role, independent of TGFβ, in cancer metastasis?
Researchers used chick embryo tumor models and a rodent model of head and neck cancer to discover how LTBP3 is involved in the spread of aggressive tumor cells. They knocked down LTBP3 expression and secretion in human tumor cell lines representing carcinoma, head and neck carcinoma and a fibrosarcoma. In each model, the team found that without LTBP3, primary tumor cells could not metastasize efficiently.
"Our experimental findings showed that LTBP3 is active in the very early steps of metastatic spread," says Quigley.
"Specifically, LTBP3 appears to help tumors grow new blood vessels in a process called angiogenesis, which is critical for tumor cell intravasation. That is when cancer cells enter into blood vessels of defined size and permeability," adds Deryugina.
Importantly, the new data is in line with clinical findings that LTBP3 levels can indicate better overall survival in cancer patients with early-stage head and neck carcinomas.
Taken together, these findings suggest LTBP3 may be a good "upstream" drug target to treat early stage tumors without affecting more complex roles of TGFβ in other parts of the body.
Researchers next plan to investigate precisely how LTBP3 and TGFβ biochemically partner in the induction of new blood vessels deep within a tumor.
Source: Eurekalert
Ovarian Cancer Metastasis can be Treated with a New Therapeutic Target
Ovarian metastasis can be treated with the inhibitors of a key cellular receptor called CXCR4, which could be a new therapeutic target.
Advertisement
Could LTBP3 set TGFβ on its harmful path of action in early-stage tumors, and might LTBP3 have its own role, independent of TGFβ, in cancer metastasis?
Researchers used chick embryo tumor models and a rodent model of head and neck cancer to discover how LTBP3 is involved in the spread of aggressive tumor cells. They knocked down LTBP3 expression and secretion in human tumor cell lines representing carcinoma, head and neck carcinoma and a fibrosarcoma. In each model, the team found that without LTBP3, primary tumor cells could not metastasize efficiently.
"Our experimental findings showed that LTBP3 is active in the very early steps of metastatic spread," says Quigley.
"Specifically, LTBP3 appears to help tumors grow new blood vessels in a process called angiogenesis, which is critical for tumor cell intravasation. That is when cancer cells enter into blood vessels of defined size and permeability," adds Deryugina.
Importantly, the new data is in line with clinical findings that LTBP3 levels can indicate better overall survival in cancer patients with early-stage head and neck carcinomas.
Taken together, these findings suggest LTBP3 may be a good "upstream" drug target to treat early stage tumors without affecting more complex roles of TGFβ in other parts of the body.
Researchers next plan to investigate precisely how LTBP3 and TGFβ biochemically partner in the induction of new blood vessels deep within a tumor.
Source: Eurekalert
Macrophages Responsible for Early Breast Cancer Metastasis
Macrophages play an important role in the metastasis of early breast cancer. Biomarkers can help identify new therapies to prevent early cancer metastasis.
Advertisement
 Antibody 15D11 With Chemotherapy Prevents Cancer MetastasisAntibody 15D11 fights bone metastasis by undermining cancer's defense strategy and allowing chemotherapy to work. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
